Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacodynamics
Daniel J. DeAngelo, Richard M. Stone, Mark L. Heaney, Stephen D. Nimer, Ronald L. Paquette, Rebecca B. Klisovic, Michael A. Caligiuri, Michael R. Cooper, Jean Michel Lecerf, Michael D. Karol, Shihong Sheng, Nick Holford, Peter T. Curtin, Brian J. Druker, Michael C. Heinrich
Dive into the research topics of 'Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacodynamics'. Together they form a unique fingerprint.